Name: Benefit-Risk Assessment of Medicines: The Development and Application of a Universal Framework for Decision-Making and Effective Communication (en Inglés)
Price: 90310.00 CLP
Availability: InStock
Author: Leong, James ; Salek, Sam ; Walker, Stuart
ISBN: 9783319367675

portada Benefit-Risk Assessment of Medicines: The Development and Application of a Universal Framework for Decision-Making and Effective Communication (en Inglés)

Formato

Libro Físico

Autor

Editorial

Idioma

Inglés

N° páginas

317

Encuadernación

Tapa Blanda

Dimensiones

23.4 x 15.6 x 1.8 cm

Peso

0.47 kg.

ISBN13

9783319367675

N° edición

Categorías

Materia antropología social y cultural etnográfica
Salud pública y medicina preventiva
Farmacología

Benefit-Risk Assessment of Medicines: The Development and Application of a Universal Framework for Decision-Making and Effective Communication (en Inglés)

Sam Salek (Autor) · Stuart Walker (Autor) · James Leong (Autor) · Adis · Tapa Blanda

Libro Nuevo

$ 90.310

$ 150.520

Ahorras: $ 60.210

40% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Viernes 21 de Junio y el Lunes 01 de Julio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Benefit-Risk Assessment of Medicines: The Development and Application of a Universal Framework for Decision-Making and Effective Communication (en Inglés)"

This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox.Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area.The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.